GPCRStructure Therapeutics Inc.
$25.51+8.2% 1Y
$25.51
$24.0152 weeks$93.79
GPCR in its own filings
GPCR's filing record carries 2 kinds of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
74
Events found in the filings · across 270 filings · the record starts in 2022
- Hard flags
- 2
Hard flags
- Most recent filing
- Sep 8, 2026
Most recent filing · Form 8-K
- Record starts
- Mar 14, 2022
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 5, 2026
- Change in certifying accountanthistorical
- 2023-06-05
- Late periodic reportpast_3y
- 2023-11-14
- SEC comment-letter activity17 occurrences
- 2024-06-04
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 8, 2026ACCG-2671 (Oral Small Molecule DACRA): Phase 1 SAD Topline Clinical Trial Results On September 8, 2026, the Company reported positive topline data for ACCG-2671, an oral, non-peptide, small molecule dual amylin and calcitonin receptor agonist (DACRA), from the SAD portion of the Phase 1/2a clinical trial.Regulation FD disclosure · Form 8-K
- Aug 6, 2026Structure Therapeutics Reports Second Quarter.Earnings release · press release
- May 7, 2026On May 7, 2026, Structure Therapeutics Inc. (the “Company”) amended and restated that certain Sales Agreement dated August 6, 2025 (the “Sales Agreement” and as amended and restated, the “Amended and Restated Sales Agreement”) with Leerink Partners LLC and Cantor Fitzgerald & Co. (collectively, the “Sales Agents”) …Material agreement entered · Form 8-K
- Apr 15, 2026Matthew Lang was appointed as Structure Therapeutics, Inc.’s (the “Company”) Chief Operating Officer and General Counsel, effective April 15, 2026.Director or officer change · Form 8-K
- Mar 16, 2026ACCESS II Study - Evaluating higher doses up to 240 mg ACCESS II is a randomized, double-blind, placebo-controlled, clinical study of aleniglipron that enrolled 85 adult participants living with obesity or overweight (defined as a BMI of greater than 25 kg/m2) with at least one weight-related comorbidity.Regulation FD disclosure · Form 8-K
- Feb 26, 2026Structure Therapeutics Reports Fourth Quarter.Earnings release · press release
- Jan 5, 2026On December 30, 2025, Gasherbrum Bio, Inc. (“Gasherbrum”), a wholly-owned subsidiary of Structure Therapeutics Inc. (the “Company”), entered into an agreement (the “GNE Agreement”) with Genentech, Inc. (“Genentech”) and F. Hoffmann-La Roche Ltd (“Roche” and together with Genentech, “GNE”) that was the culmination of …Material agreement entered · Form 8-K
- Dec 10, 2025Follow-on Public Offering On December 9, 2025, Structure Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, Leerink Partners LLC, Goldman Sachs & Co. LLC and Morgan Stanley & Co. LLC, as representatives of the several underwriters named therein …Other event · Form 8-K
- Dec 8, 2025Summary of Data from the ACCESS Clinical Program The Company’s ACCESS clinical program includes 36-week data from the core Phase 2b ACCESS study and exploratory ACCESS II study, and interim data from Phase 2 body composition study and Phase 2b ACCESS open label extension (OLE) study, as follows: • The Phase 2b ACCESS …Regulation FD disclosure · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…